VENTRIPOINT DIAGNOSTICS LTD. (the "Corporation" or "VentriPoint") (TSX
VENTURE:VPT) announces that it filed its audited consolidated annual financial
statements and related management's discussion and analysis ("MD&A") for the
year ended December 31, 2009. These filings are available in their entirety at
www.sedar.com.


The Corporation also announces it intends to complete a private placement of up
to 12,500,000 common shares of the Corporation (the "Common Shares") at a price
of $0.12 per Common Share for gross proceeds of up to $1,500,000 (the "Private
Placement"). The Corporation intends to use the proceeds from the Private
Placement to incur expenditures in preparation for and implementation of product
and service commercialization and for working capital purposes. Pursuant to the
Private Placement, VentriPoint may pay cash commissions and grant
non-transferable agent's options equal to 10% of the proceeds raised to
qualified agents exercisable for a period of 18 months from closing in
accordance with the policies of the TSX Venture Exchange (the "TSX Venture").
Completion of the Private Placement is subject to final approval of the board of
directors of the Corporation and the approval of TSX Venture. The Common Shares
will be subject to a four-month hold period, in accordance with applicable
securities law.


The Corporation also announces that, pending TSX Venture approval, it intends to
issue 561,235 Common Shares to holders of secured, subordinated, debentures of
the Corporation (the "Secured Debentures") in satisfaction of interest due on
the Secured Debentures in accordance with the terms of the Secured Debentures.
The Common Shares will be issued at a deemed price of $0.15 per share to the
holders of the Secured Debentures and will have a hold period of four months
from the date of issuance in accordance with applicable securities legislation.


The Corporation also announces that, subject to TSX Venture approval, it has
entered into a settlement agreement (the "Settlement Agreement") with Joseph
Ashley, the President, CEO and a director of the Corporation, whereby Mr. Ashley
has agreed to cancel a promissory note (the "Note") dated October 20, 2008 in
the amount of $861,712 in exchange for $861,712 of secured debentures (the
"Debentures") with an interest rate of 8% per annum and 3,446,848 warrants of
the Corporation exercisable for three years from the date of issuance at $0.125
per share.


The Corporation also announces that it has granted 273,000 options to CHF
Investor Relations ("CHF") in accordance with the Investor Relations Agreement
dated September 22, 2008 between the Corporation and CHF. The options are
exercisable at $0.15 per share until the fifth anniversary date of the grant.


About VentriPoint Diagnostics

VentriPoint creates diagnostic tools to monitor patients with heart disease -
the number one cause of death in developed countries. By using images produced
from existing medical imaging systems, the VentriPoint Medical System ("VMS")
generates critical heart measurements in a rapid and inexpensive manner not
currently available. The VMS is being adapted for a variety of heart-related
diseases, with congenital heart disease representing the first application, and
applications for pulmonary hypertension, cardiovascular disease and heart
failure in process to follow. Canada and Europe have granted license approval
for the VMS diagnostic tool, and VentriPoint is gathering additional requested
information in support of its 510(k) submission to the U.S. Federal Drug
Administration.


To receive press releases, please email chris@chfir.com and mention VentriPoint
in the subject line


The securities described in this press release have not been, nor will be,
registered under the United States Securities Act of 1933, as amended, and such
securities may not be offered or sold within the United States or to, or for the
account or benefit of, U.S. persons absent U.S. registration or an applicable
exemption from U.S. registration requirements. This release does not constitute
an offer for sale of securities in the United States.
Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Vortex Metals Charts.
Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Vortex Metals Charts.